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Objective. To compare the occurrence of pre-existing and subsequent comorbidity among older cancer patients (≥ 60 years) with
older non-cancer patients. Material and Methods. Each cancer patient (n = 3835, mean age 72) was matched with four non-cancer
patients in terms of age, sex, and practice. The occurrence of chronic diseases was assessed cross-sectionally (lifetime prevalence
at time of diagnosis) and longitudinally (incidence after diagnosis) for all cancer patients and for breast, prostate, and colorectal
cancer patients separately. Cancer and non-cancer patients were compared using logistic and Cox regression analysis. Results. The
occurrence of the most common pre-existing and incident chronic diseases was largely similar in cancer and non-cancer patients,
except for pre-existing COPD (OR 1.21, 95% CI 1.06–1.37) and subsequent venous thrombosis in the first two years after cancer
diagnosis (HR 4.20, 95% CI 2.74–6.44), which were significantly more frequent (P < 0.01) among older cancer compared to non-
cancer patients. Conclusion. The frequency of multimorbidity in older cancer patients is high. However, apart from COPD and
venous thrombosis, the incidence of chronic diseases in older cancer patients is similar compared to non-cancer patients of the
same age, sex, and practice.
1. Introduction
With advances in early detection and cancer treatments,
numbers of cancer survivors are rising [1], and with the
ageing of the population, the number of older cancer
survivors will continue to rise even if age-specific incidence
rates remain constant [2]. Whereas cancer used to be a
fatal disease, it is now developing towards a chronic or even
curable disease [3, 4]. At present, more than 60% of older
cancer patients suﬀer from one or more chronic diseases [5].
Because of the chronic character of cancer [6] and the high
level of comorbidity [7], the role of general practitioners
(GPs) in cancer aftercare will becomemore prominent [7, 8].
Studies among cancer survivors have shown that the
consequences of cancer treatment are numerous and depend
on the type of cancer and treatment characteristics [4, 9].
The most common sequelae are second malignancies (due
to genetic or environmental risk factors shared with the first
tumour and treatment-related factors) and cardiovascular
diseases as myocardial infarction and cardiac insuﬃciency
(due to radiotherapy as well as chemotherapy) [9]. Many
other diseases, such as osteoporosis [10] and diabetes [11],
have been related to cancer treatment also. These late eﬀects
are also common ageing-related diseases. Therefore, within
primary care, which is characterized by a heterogeneous
patient population and “only” 50 cancer patients per stan-
dard practice (of 2350 patients) [12], the late eﬀects of cancer
and its treatment could easily be mistaken for normal ageing
and dismissed as such in older cancer survivors [13]. Given
the GPs’ expertise in dealing with multimorbidity, we believe
that GPs could play an important role in aftercare for cancer
survivors. Hence, primary care providers are in urgent need
of more knowledge on the interaction between cancer, cancer
treatment, and comorbidity in older cancer patients.
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Therefore, we aim to examine from a generic GP per-
spective the occurrence of pre-existing (prevalent) and sub-
sequent (incident) chronic diseases among cancer patients
aged over 60, in comparison with non-cancer patients of the
same age, sex, and practice in a large retrospective primary
care-based cohort study.
2. Materials andMethods
2.1. The Registration Network Family Practices. This study
was carried out within the context of the Registration Net-
work Family Practices (RegistratieNet Huisartspraktijken,
RNH) [14]. This is a continuously updated computerized
primary care database, with a target population of about
135,000 people. All relevant health problems are routinely
recorded using a computerized health information system.
All participants were informed about the anonymous use of
information about their health status when they registered
as patients with the participating general practices (21
participating practices and about 65 general practitioners).
All relevant health problems—current as well as past—
are recorded on a problem list. A health problem is defined
as “anything that has required, does or may require health
care management and has aﬀected or could significantly
aﬀect a persons’ physical or emotional well-being.” Health
problems are coded using the International Classification
of Primary Care (ICPC), following the criteria of the
International Classification of Health Problems in Primary
Care (ICHPPC-2-defined) for diagnoses [14]. In the Nether-
lands, GPs have comprehensive information on the health
status of their patients because GPs function as gatekeepers
to other health care facilities, and it is compulsory for
all Dutch residents to have health care insurance and to
register with a GP. Hence, we can expect the registered
population to be representative of the general population.
In addition to medical information, the RNH database also
contains background information on sex, date of birth, living
arrangement, level of education, and the date and reason
of removal. RNH registration only ends upon migration or
death. The quality of the data is assured by instruction and
training sessions, regional consensus groups, quality control
experiments, and special software programs, such as an
automated thesaurus and automated checking for erroneous
or missing entries [14]. Reliability and completeness have
been proved previously [15].
2.2. Design and Data Analysis. The design of this study
is a retrospective cohort, including all patients who were
members of the RNH database between 1 January 1998 and
31 December 2010, and aged 60 years and over. Patients
with a previous cancer history (diagnosed before January
1998) were excluded. Neoplasms of the skin were excluded
as well, as due to the ICPC coding we were unable to
distinguish between benign and malign neoplasma of the
skin. Each cancer patient, diagnosed between January 1998
and December 2010 (n = 3835), was matched with four
non-cancer patients based on age, sex, and practice. For 239
cancer patients, we were unable to find an appropriatematch.
337, 428, 429, and 3596 cancer patients were matched with
one, two, three, and four non-cancer patients respectively.
Matched non-cancer patients were assigned a reference date
(the same as the date of the cancer diagnosis of their matched
cancer patient).
Only ICPC codes that correspond to severe or chronic
diseases were selected and categorized as previously
described by Knottnerus et al. [16] (please see Table 1 in the
Supplementary Material available online at doi:10.1155/-
2012/206414).
Pre-existing chronic diseases were defined as all diag-
noses established before the cancer diagnosis or reference
date. Subsequent chronic diseases were defined as all diag-
noses established after the cancer diagnosis or reference date.
All diagnoses that were established within a 3-month period
before removal from the RNH database were excluded, as
these might reflect the palliative phase, in which the disease
pattern might be diﬀerent. Pre-existing chronic diseases were
assessed by calculating the lifetime prevalence (per 1000
persons) cross-sectionally at the time of the cancer diagnosis
or the reference date and were compared between cancer
patients and their matched non-cancer patients using logistic
regression analyses, adjusted for age and sex. Prevalence and
odds ratios were calculated for all cancer patients together,
and for breast, prostate, and colorectal cancer patients
separately. The occurrence of subsequent chronic diseases
was longitudinally assessed by calculating the incidence per
1000 person-years at risk, excluding patients with a previous
diagnosis of the disease. Hazard ratios and their 95%
confidence intervals (95% CIs) were calculated using mul-
tivariate Cox regression analyses, adjusted for age, sex, and
presence of cardiovascular diseases, respiratory diseases, or
diabetes at baseline (please see Table 1 in the Supplementary
Material on the journal website for the precise cardiovascular
and respiratory diseases which were included). Incidence
and hazard ratios were computed for all cancer patients
in comparison with their age, sex, and practice-matched
controls and for all breast, prostate, and colorectal cancer
patients separately, in comparison with their respective
matched controls. The proportional hazards assumption was
tested using Schoenfeld residuals. For venous thrombosis
(K93+K94), limited mental function (P28), lipid disorders
(T93), and other endocrine/metabolic/nutritional diseases
(T99), proportional hazards assumption was violated. This
was resolved by splitting the survival time.
Analyses were processed with the STATA statistical soft-
ware package (StataCorp. 2009. Stata: Release 11. Statistical
Software. College Station, TX: StataCorp LP). Throughout
all analyses, a two-sided P-value <0.01 was used as the cut-
oﬀ point for statistical significance.
3. Results
3.1. Population. In the thirteen-year study period (1998–
2010), there were 3,835 patients with a first diagnosis of
cancer who were 60 years or older at the time of their cancer
diagnosis (see Table 1). These cases were matched to 11,973
controls.
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Table 1: Characteristics of older cancer patients and non-cancer
patients at time of cancer diagnosis or reference date.
Cancer patients Non-cancer patients
(N = 3835) (N = 11973)
Mean (SD) Mean (SD)
Age (years)
Men 71.95 (7.35) 70.87 (7.13)
Women 73.22 (8.42) 72.90 (8.27)
Survival time (years)1
Men 2.92 (3.06) 3.87 (3.15)
Women 3.32 (3.39) 4.17 (3.27)
N (%) N (%)
Sex
Men 2163 (56) 6179 (52)
Women 1672 (44) 5794 (48)
Number of chronic diseases at baseline2
0 846 (22) 2617 (22)
1 908 (24) 2916 (24)
2 752 (20) 2288 (19)
3 534 (14) 1682 (14)
≥4 795 (21) 2470 (21)
Five most common tumour sites
Colon/rectum 675 (18)
Prostate 573 (15)
Bronchus/lung 550 (14)
Breast 493 (13)
Bladder 218 (7)
1
Survival time: time from date of diagnosis or reference date until death or
end of follow-up.
2Number of chronic diseases excluding cancer.
3.2. Pre-Existing Chronic Diseases. The prevalence of pre-
existing chronic diseases was high; 78% of all cancer patients
had at least one disease additional to the malignancy at time
of cancer diagnosis (see Table 1).
The most common pre-existing chronic diseases were
the same for cancer patients and non-cancer patients.
These were diabetes, lipid disorders, ischemic heart disease,
myocardial infarction, and COPD. COPD was significantly
more prevalent among cancer patients compared to non-
cancer patients (OR 1.21, 95% CI 1.06–1.37). Furthermore,
dementia (OR 0.48, 95% CI 0.36–0.64) and personality
disorder (OR 0.53, 95% CI 0.33–0.84) were significantly less
prevalent in cancer patients compared to non-cancer patients
(see Table 2).
When stratified by cancer type (data not shown), we
found no diﬀerences within breast cancer patients (n = 493)
compared to their matched controls (n = 1675). For prostate
cancer patients (n = 573) compared to their respective
controls (n = 1604), we found a higher prevalence of benign
prostatic hypertrophy (OR 1.44, 95% CI 1.09–1.88) and a
lower prevalence of stroke (OR 0.40, 95% CI 0.25–0.65) and
diabetes (OR 0.67, 95% CI 0.51–0.90). For colorectal cancer
patients (n = 675) in comparison with their controls (n =
2063), we found a higher prevalence of blindness (OR 2.85,
95%CI 1.43–5.71) and a lower prevalence of stroke (OR 0.60,
95% CI 0.41–0.89), dementia (OR 0.26, 95% CI 0.12–0.56),
and benign prostatic hypertrophy (OR 0.55, 95% CI 0.36–
0.83).
3.3. Subsequent Chronic Diseases. Just as for pre-existing
chronic diseases, risk of subsequent chronic diseases was
similar among cancer survivors and non-cancer patients.
The most common incident diseases in cancer patients
were diabetes, venous thrombosis, osteoporosis, COPD, and
heart failure. In non-cancer patients these were diabetes,
benign prostatic hypertrophy, stroke, dementia, and COPD.
In cancer survivors, the incidence of subsequent venous
thrombosis was significantly higher compared to non-
cancer patients during the first two years of survival (HR
4.20, 95% CI 2.74–6.44). Thereafter, this diﬀerence was no
longer statistically significant (see Table 3). Furthermore, the
incidence of hypertension with organ damage (HR 0.66, 95%
CI 0.48–0.92), lipid disorders during the first two years after
diagnosis (HR 0.49, 95% CI 0.29–0.82), and benign prostatic
hypertrophy (HR 0.46, 95% CI 0.31–0.69) was significantly
lower in cancer patients compared to non-cancer patients
(see Table 3).
When stratified by cancer type (data not shown), we
found no diﬀerences for breast cancer patients compared
to their respective controls. In prostate cancer patients, the
incidence of venous thrombosis (HR 7.10, 95% CI 2.25–
22.40) was significantly higher compared to non-cancer
patients, and the incidence of benign prostatic hypertrophy
was significantly lower (HR 0.17, 95% CI 0.06–0.48). In
colorectal cancer patients, the incidence of venous throm-
bosis (HR 2.43, 95% CI 1.22–4.81) was significantly higher
compared to non-cancer patients.
4. Discussion
4.1. Principal Findings. The number of chronic diseases
additional to cancer proved to be high and is probably
associated with high age in the first place. Both prevalence
at diagnosis and incidence, however, tend to be largely
similar in older cancer and non-cancer patients. The latter
is consistent with recent other studies [17, 18].
4.2. Pre-Existing Chronic Diseases. At time of cancer diag-
nosis, 78% of all cancer patients had at least one disease
additional to the malignancy. This highlights the enormous
burden of comorbidity in older cancer patients. However,
from the perspective of a GP, it is also important that
cancer and non-cancer patients were similar with respect
to prevalence of chronic diseases. Still, there were some
exceptions. In cancer patients, the prevalence of COPD was
significantly higher compared to non-cancer patients. When
stratified by cancer type, this diﬀerence remained significant,
only within the group of lung cancer patients (OR 2.88, 95%
CI 2.20–3.78) (data not shown). This is in line with previous
reports [19] and is probably due to shared risk factors such as
smoking [20]. Based on previous studies on the interaction
between cancer and comorbidity, we would have expected an
4 Journal of Cancer Epidemiology
Table 2: Pre-existing chronic diseases in men and women.
Cancer patients Non-cancer patients
P-value OR2 (95% CI)
N Prev1 N Prev1
Ten most common pre-existing diseases in cancer patients
Diabetes mellitus 586 152.80 1864 155.68 0.48 0.96 (0.87–1.07)
Lipid disorders 508 132.46 1559 130.21 0.60 1.03 (0.92–1.15)
Ischemic heart disease with angina 459 119.69 1326 110.75 0.73 1.02 (0.91–1.14)
Myocardial infarction 405 105.61 1162 97.05 0.86 1.01 (0.90–1.14)
Ischemic heart disease without angina 393 102.48 1151 96.13 0.98 1.00 (0.88–1.13)
Chronic obstructive pulmonary disease 382 99.61 944 78.84 0.00 1.21 (1.06–1.37)
Osteoarthrosis knee 312 81.36 1054 88.03 0.17 0.91 (0.80–1.04)
Benign prostatic hypertrophy 297 77.44 740 61.81 0.33 1.08 (0.93–1.25)
Back syndrome without radiating pain 281 73.27 888 74.17 0.70 0.97 (0.85–1.12)
Osteoarthrosis hip 272 70.93 885 73.92 0.47 0.95 (0.82–1.09)
Significant diﬀerences between cancer and non-cancer patients3
Dementia 60 15.65 344 28.73 0.00 0.48 (0.36–0.64)
Personality disorder 21 5.48 127 10.61 0.01 0.53 (0.33–0.84)
1
Prev: lifetime prevalence per 1000 persons.
2OR: odds ratio adjusted for sex and age.
3Please see Table 2 in the Supplementary Material on the journal website for all other diseases.
Table 3: Subsequent chronic diseases in men and women.
Cancer survivors Non-cancer patients
P-value HR2 (95% CI)
N Inc1 N Inc1
Ten most common subsequent diseases in cancer patients
Diabetes mellitus† 133 13.46 589 14.79 0.31 0.91 0.75 1.09
Venous thrombosis
Baseline—2 years 45 9.27 40 2.11 0.00 4.20 2.74 6.44
2 years—end of follow-up† 20 3.10 58 2.11 0.15 1.45 0.87 2.41
Osteoporosis 99 8.93 354 7.90 0.15 1.18 0.94 1.47
Chronic obstructive pulmonary disease 95 8.81 378 8.56 0.97 1.00 0.80 1.25
Heart failureδ 94 8.31 380 8.28 0.80 0.97 0.77 1.22
Stroke/cerebrovascular accident 92 8.27 435 9.81 0.08 0.82 0.65 1.03
Dementiaβ 83 7.16 417 8.93 0.07 0.81 0.64 1.02
Ischemic heart disease without anginaβ 71 6.76 308 7.17 0.50 0.92 0.71 1.19
Ischemic heart disease with angina 65 6.29 294 7.03 0.36 0.88 0.67 1.15
Osteoarthrosis hip 66 6.05 268 6.11 0.95 1.01 0.77 1.32
Significant diﬀerences between cancer and non-cancer patients3
Hypertension with organ damage 41 3.67 250 5.55 0.01 0.66 0.48 0.92
Lipid disorders
Baseline—2 years 16 3.66 129 7.62 0.01 0.49 0.29 0.82
2 years—end of follow-up 31 5.27 171 7.08 0.16 0.76 0.52 1.11
Benign prostatic hypertrophy 27 5.05 223 10.87 0.00 0.46 0.31 0.69
1
Inc: incidence per 1000 person years at risk.
2HR: hazard ratio adjusted for sex, age, cardiovascular diseases, respiratory diseases, and diabetes.
3Please see Table 3 in the Supplementary Material on the journal website for all other diseases.
†Adjusted for age as time-varying coeﬃcient.
δAdjusted for sex and age as time-varying coeﬃcient.
βAdjusted for cardiovascular diseases as time-varying coeﬃcient.
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increased prevalence of diabetes in colorectal cancer patients
[21]. The point estimator was higher than one, but the
absolute diﬀerence was small and not statistically significant.
We found a significant lower prevalence of dementia in
cancer patients compared to non-cancer patients. This has
been previously reported and is also known as inverse cancer
comorbidity [22]. Probably, malignancies are not less fre-
quently occurring, but less frequently diagnosed in patients
with dementia. In line with Tabare´s-Seisdedos et al., we also
found inverse comorbidity for diabetes in prostate cancer
patients [22], whichmay be related to diabetes treatment [23,
24]. Furthermore, we showed inverse comorbidity for stroke
in both prostate and colorectal cancer patients. A negative
association between prostate and colorectal cancer and stroke
was also shown by others [17], however, a clear explanation
is still lacking [25]. In this perspective Tabare´s-Seisdedos
et al. stated that “further research is needed as analyses
of inverse cancer comorbidity can help us understand why
some people are protected from certain cancers, and might
help to uncover the mechanisms underlying malignancy”
[22].
4.3. Subsequent Chronic Diseases. After cancer diagnosis
we showed similar to pre-existing diseases that the most
common new diseases in cancer survivors were also the most
common ones in non-cancer survivors. In line, a recent
and similar study by Khan et al. showed that long-term
cancer survivors are a population at risk but that the absolute
increase in disease burden is small [26].
For venous thrombosis we showed a significantly
increased hazard ratio during the first two years of survival.
This is in line with previous studies on consequences of
cancer treatment [27] and was also confirmed for breast (P-
value 0.03), prostate (P-value 0.00), and colorectal (P-value
0.01) cancer patients separately. Therefore, GPs should be
alert for the occurrence of venous thrombosis in older cancer
survivors, especially within the first two years after diagnosis.
Although it is not the scope of this study, we were
unable to confirm a higher incidence of osteoporosis (due
to hormone replacement therapy), hypothyroidism (due
to radiotherapy), and heart failure (due to radiotherapy
and chemotherapy) in specific groups of cancer survivors
compared to non-cancer survivors [26]. This may result from
small absolute diﬀerences and a lower power of our study.
Furthermore, the time frame of our study does not enable
us to study the occurrence of late eﬀects of cancer therapy.
As described by Hewitt et al. “late eﬀects appear months
to years after the completion of therapy” [4]. However, we
continue our followup of the included patients and hope to
come forward with late eﬀect results at a later time.
Besides the increased risk for venous thrombosis, we
found a lower incidence of hypertension with organ damage
and lipid disorders (only during the first two years after
cancer diagnosis) in cancer patients compared to non-cancer
patients. In the first period after diagnosis, a decrease in food
intake due to side eﬀects of treatment and emotional factors,
and later increased surveillance, and attention for healthy
lifestyle might explain this lower incidence. A recent study
showed, however, no obvious diﬀerence in lifestyle factors
among short- and long-term cancer survivors compared to
controls [28]. Furthermore, data on hyperlipidemia have
been previously shown to be heterogeneous [21]. We also
found a significant lower incidence of benign prostatic
hypertrophy in all cancer patients compared to non-cancer
patients. As expected, when stratified by cancer type, this
diﬀerence only remained for prostate and bladder cancer
patients (data not shown).
4.4. Strengths and Limitations. An important strength of this
study was that the comprehensive registration of diseases was
based on GPs’ daily practice and that this data was analysed
in a retrospective cohort design.
A shortcoming of this study was that information on can-
cer treatment and smoking status was incomplete. Therefore
we were unable to analyse the risk of comorbidity according
to treatment type and to consider smoking as a confounder.
This is an important drawback because late eﬀects in cancer
survivors are treatment specific [4]. However, to assess the
consequences of cancer treatment as such was beyond the
scope of this study. The aim of this study was to assess
the frequency of comorbidity in cancer patients from a
GP perspective, who sees only a small number of cancer
patients (about 50 per standard practice) with very diverse
cancer types. Hence, we aimed to assess in a generic way
the disease burden in older cancer patients, and we aimed
to assess whether these cancer patients present to their GP
with diﬀerent diseases compared to non-cancer patients of
the same age, sex, and practice.
Another limitation was that some associations may
have occurred by chance (Type I error) due to multiple
comparisons. The chance of Type I errors can be dimin-
ished by applying a Bonferroni correction. However, this
would dramatically increase the chance for Type II errors.
According to Rothman it is not necessary to correct for
multiple comparisons as the underlying premise of research
is that nature follows regular laws that may be studied
through observation [29, 30]. Therefore, we decided not
to formally correct for multiple comparisons and to use a
P-value of 0.01 as cut-oﬀ for statistical significance. This
does, however, not prohibit that some findings might have
occurred due to chance, such as the increased prevalence
of blindness, and the decreased prevalence of prostatic
hypertrophy in colorectal cancer patients, and personality
disorders in cancer patients in general. Furthermore, we
showed that prostatic hypertrophy was more prevalent in
prostate cancer patients, which is probably due to indication
bias. Therefore, it is important that these results are validated
in similar cohorts.
Because of the similarities between older cancer and
non-cancer patients and the GPs’ expertise in dealing
with multimorbidity, we believe that GPs could play an
important role in aftercare for cancer survivors. However,
the participation of primary care in cancer care is still in
its infancy. Hence, further research is needed. Future studies
could focus on the coordination of aftercare between primary
and secondary care, the development of guidelines for cancer
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patients with comorbidity, and the use of patient goals in the
determination of care planning in patients with complex care
needs.
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